highly significantP < 0.001
57 Results for the primary endpoint of complete clearance were also highly significant, favoring ingenol mebutate in each of the four individual studies ( P < 0.001). 57 The efficacy of ingenol mebutate varied according to anatomic location, with higher rates of complete clearance associated with facial AK (ingenol mebutate versus vehicle, 47.3% versus 4.1%; P < 0.001) than with scal